The findings revealed that SLFN5, SLFN11, SLFN12, SLFN12L, SLFN13, and SLFN14 were expressed at higher levels in many cancers, including GC (stomach adenocarcinoma; STAD), while the SLFN14 expression levels were relatively low in all tumor and normal tissues (Figures 1A–F). This evidence concerns the gene SLFN5 and neoplasm.